Having proven the efficacy of its bone-graft product for the foot and ankle in a Canadian pivotal trial, BioMimetic Therapeutics Inc. is selling rights for the marketed periodontal therapy based on the same platform, thereby gaining $40 million in cash that will be used for other product development. (BioWorld Today) Read More
